RxDoctor Payments Data

Bikram Bal

Gastroenterology · Farmville, VANPI 1699932517

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,100 of the $40,470 with a category attached, or 84.3%. AbbVie accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $26,547 and has fallen 99.9% since, to $14 in 2024. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,470in general payments, 2019–2025

Across 78 payments — averaging $518.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$40K
  • Boston Scientific$147
  • Takeda Pharmaceuticals U.S.A., Inc.$91
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$27

What the payments were for

  • Speaking & faculty fees$34,10084%
  • Travel & lodging$5,22113%
  • Food & beverage$1,1403%
  • Education$90%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,470 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$157,655
Medicare patients
614
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase50$273,186
ZenpepLipase/Protease/Amylase26$150,235
Humira(Cf) PenAdalimumab13$89,653
LinzessLinaclotide18$17,065
Balsalazide Disodium24$6,151
Mesalamine DrMesalamine12$5,214
Mesalamine ErMesalamine14$4,212
Omeprazole295$3,243
Ursodiol21$2,610
Budesonide DrBudesonide11$1,672
Pantoprazole Sodium108$1,445
Famotidine13$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$40,205$290,25168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Farmville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →